title: In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus.
abstract: To compare the in vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistant Staphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.
authors: Departments of Medicine.
authors: Hung-Jen
authors: HJ
authors: Tang
authors: Chi-Chung
authors: CC
authors: Chen
authors: Kuo-Chen
authors: KC
authors: Cheng
authors: Kuan-Ying
authors: KY
authors: Wu
authors: Yi-Chung
authors: YC
authors: Lin
authors: Chun-Cheng
authors: CC
authors: Zhang
authors: Tzu-Chieh
authors: TC
authors: Weng
authors: Wen-Liang
authors: WL
authors: Yu
authors: Yu-Hsin
authors: YH
authors: Chiu
authors: Han-Siong
authors: HS
authors: Toh
authors: Shyh-Ren
authors: SR
authors: Chiang
authors: Bo An
authors: BA
authors: Su
authors: Wen-Chien
authors: WC
authors: Ko
authors: Yin-Ching
authors: YC
authors: Chuang
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D004357:Drug Synergism; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D008826:Microbial Sensitivity Tests; D059645:Mutation Rate; D063065:Organophosphonates / Q000494:pharmacology; D023303:Oxazolidinones / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology*; D013261:Sterols / Q000494:pharmacology; D013754:Tetracyclines / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D063065:Organophosphonates; D023303:Oxazolidinones; D010456:Peptides, Cyclic; D013261:Sterols; D013754:Tetracyclines; D012293:Rifampin
references: Microb Drug Resist. 2000 Fall;6(3):189-98
references: 11144419
references: Clin Infect Dis. 2006 Feb 1;42(3):394-400
references: 16392088
references: J Antimicrob Chemother. 2001 May;47(5):647-50
references: 11328777
references: J Clin Microbiol. 1995 Sep;33(9):2233-9
references: 7494007
references: Antimicrob Agents Chemother. 2006 Jan;50(1):55-61
references: 16377667
references: Clin Infect Dis. 2011 Feb 1;52(3):e18-55
references: 21208910
references: Antimicrob Agents Chemother. 2009 Oct;53(10):4172-7
references: 19620326
references: BMJ. 2009 May 29;338:b1773
references: 19482869
references: J Clin Microbiol. 2007 Jul;45(7):2173-9
references: 17494717
references: Clin Infect Dis. 2004 Feb 15;38(4):521-8
references: 14765345
references: Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):171-80
references: 19946789
references: Am J Surg. 2006 Sep;192(3):344-54
references: 16920429
references: J Microbiol Immunol Infect. 2013 Apr;46(2):89-95
references: 22572005
references: Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):61-2
references: 16331332
references: Antimicrob Agents Chemother. 2007 May;51(5):1656-60
references: 17353249
references: Int J Antimicrob Agents. 2011 Jul;38(1):46-51
references: 21549575
references: J Antimicrob Chemother. 2012 Apr;67(4):944-50
references: 22258931
references: N Engl J Med. 2002 Oct 3;347(14):1110-1
references: 12362015